期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 15, 期 3, 页码 127-128出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2018.11
关键词
-
类别
In 2017, FDA Oncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic applications, and two biosimilar applications in oncology. These actions included landmark approvals of two chimeric antigen receptor T cell therapies and the first site-agnostic, biomarker-defined approval. Three next-generation sequencing 'oncopanels' designed to detect hundreds of somatic genetic aberrations were also approved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据